Infanrix Polio

Poliovirus (inactivated) type 3 (Saukett strain) and pertussis filamentous haemagglutinin, the active ingredient in Infanrix Polio, is a vaccine presented as an injectable vaccine for intramuscular use. It is used to prevent poliomyelitis caused by poliovirus type 3 and pertussis (whooping cough) in infants and young children.

GNH USA supplies Infanrix Polio as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Infanrix Polio is a combination vaccine that targets viral and bacterial pathogens involved in childhood respiratory and neurological disease. - Poliomyelitis (type 3): provides active immunity to prevent paralytic poliomyelitis caused by poliovirus type 3. - Pertussis (whooping cough): induces protective antibodies against pertussis filamentous haemagglutinin to reduce severe cough illness. - Routine infant immunisation: incorporated into national childhood vaccination schedules to achieve community protection against both diseases.

Common Side Effects: - Injection site pain, redness or swelling: mild local reactions at the site of administration. - Low‑grade fever: transient elevation of body temperature within 24‑48 hours. - Irritability or fussiness: typical behavioural response in young children after vaccination.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Seizures (febrile convulsions): rare occurrence associated with high fever. - Hypotonic‑hyporesponsive episode: brief loss of muscle tone and reduced responsiveness. - Persistent high fever: fever lasting more than 48 hours or exceeding 40°C. - Severe allergic rash or angioedema: extensive skin involvement or swelling.

Before administering Infanrix Polio, healthcare professionals should consider the following precautions. - Allergy assessment: verify no known hypersensitivity to any vaccine component. - Acute illness: postpone vaccination if the child has a moderate or severe febrile illness. - Immunocompromised status: evaluate risks in patients with severe immunodeficiency. - Pregnancy and lactation: safety not established; use only if benefits outweigh potential risks. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Vaccines may interact with other agents that modify immune responses. Major Interactions (Avoid): - Live attenuated vaccines: avoid simultaneous administration; schedule according to recommended intervals. - Immunoglobulin therapy: may diminish vaccine‑induced immunity if given concurrently. Moderate Interactions (Monitor Closely): - Antipyretics (e.g., prophylactic acetaminophen): could blunt antibody response when given before vaccination. - Corticosteroids: high‑dose systemic steroids may reduce immunogenicity; monitor antibody levels if clinically indicated.